Poway, California (PRWEB) January 16, 2015

January 16th, 2015 Leading Regenerative Veterinary Medicine company, Vet-Stem, Inc., CEO announced the hiring of President and Chief Commercial Officer, Alexis Nahama, DVM.

After ten years of market presence, serving early adopter and progressive veterinarians, we are ready to take our company to the next level. We are heavy on science, and have engaged in the development of our next generation of therapeutic solutions, including working with the FDA towards obtaining approval for the first veterinary cellular therapy product to be used in helping dogs affected by osteoarthritis. In addition to its aim of reducing the pain of osteoarthritis, this therapy has the potential to impact the progression of the disease, and to promote tissue regeneration. Given the complexities of such developments, I have decided to focus most of my time to our research programs. I needed a great partner to take on the current operations and focus our commercial approach, said Dr Bob Harman (CEO).

Dr. Harman and the board of directors announced the appointment of Dr. Alexis Nahama as the new Vet-Stem, Inc.s President and Chief Commercial Officer.

Dr. Nahama, former head of marketing for VCA Inc. (Nasdaq: Woof), brings two decades of global veterinary industry experience with him, ranging from clinical development to managing some of the most influential brands in animal health.

Our current technology has helped over 10,000 dogs, horses and cats through processing of their own fat tissue to extract stem cells that are then injected in painful joints, tendons or ligaments, but many owners are still unaware we have a possible solution for their animals need. Although not inexpensive, (great breakthrough technologies seldom are) this therapeutic approach is already available through many veterinarians today! said Dr Nahama.

Vet-Stem Inc., despite its relatively small size has the potential to dramatically change the way veterinarians address difficult diseases in the not so distant future. In a world of giant corporations, this company will be truly disruptive and benefit countless patients worldwide. It is with great pride and excitement that I take on these responsibilities and join this amazingly smart and dedicated group of people,added Dr. Nahama.

Alexis passion for helping pet owners and veterinarians, coupled with his extensive knowledge of the veterinary industry and his marketing expertise, is exactly what we need to succeed, stated Dr. Harman. I am happy to welcome him to be part of our leadership team.

About Vet-Stem, Inc. Vet-Stem, Inc. was formed in 2002 to bring regenerative medicine to the veterinary profession. This privately held biotechnology enterprise, based near San Diego (California), currently offers veterinarians access to stem-cell therapy (extracted from the patients own fat tissue), among other regenerative treatment modalities. With over 10,000 patients treated by veterinarians for joint, tendons and ligament issues, Vet-Stem has made regenerative medicine applications a therapeutic reality beyond the realm of research. Development programs focused on products and services that utilize the natural tissue healing properties inherent in all living creatures, have the potential to dramatically improve the quality of life for our animals Vet-Stems progress in bringing practical and affordable medical solutions to market might change animal lives by improving the quality of recovery in acute conditions, but also by unlocking ways to slow, stop and ultimately revert the course of chronic diseases.. Vet-Stem currently holds the exclusive licenses to over 55 patents including worldwide veterinary rights for use of adipose derived stem cells, with over 75 patents pending.

12860 Danielson Court, Suite B Poway, CA 92064 858-748-2004

More here:
Stem Cells Therapy

Poway, California (PRWEB) January 16, 2015

January 16th, 2015 Leading Regenerative Veterinary Medicine company, Vet-Stem, Inc., CEO announced the hiring of President and Chief Commercial Officer, Alexis Nahama, DVM.

After ten years of market presence, serving early adopter and progressive veterinarians, we are ready to take our company to the next level. We are heavy on science, and have engaged in the development of our next generation of therapeutic solutions, including working with the FDA towards obtaining approval for the first veterinary cellular therapy product to be used in helping dogs affected by osteoarthritis. In addition to its aim of reducing the pain of osteoarthritis, this therapy has the potential to impact the progression of the disease, and to promote tissue regeneration. Given the complexities of such developments, I have decided to focus most of my time to our research programs. I needed a great partner to take on the current operations and focus our commercial approach, said Dr Bob Harman (CEO).

Dr. Harman and the board of directors announced the appointment of Dr. Alexis Nahama as the new Vet-Stem, Inc.s President and Chief Commercial Officer.

Dr. Nahama, former head of marketing for VCA Inc. (Nasdaq: Woof), brings two decades of global veterinary industry experience with him, ranging from clinical development to managing some of the most influential brands in animal health.

Our current technology has helped over 10,000 dogs, horses and cats through processing of their own fat tissue to extract stem cells that are then injected in painful joints, tendons or ligaments, but many owners are still unaware we have a possible solution for their animals need. Although not inexpensive, (great breakthrough technologies seldom are) this therapeutic approach is already available through many veterinarians today! said Dr Nahama.

Vet-Stem Inc., despite its relatively small size has the potential to dramatically change the way veterinarians address difficult diseases in the not so distant future. In a world of giant corporations, this company will be truly disruptive and benefit countless patients worldwide. It is with great pride and excitement that I take on these responsibilities and join this amazingly smart and dedicated group of people,added Dr. Nahama.

Alexis passion for helping pet owners and veterinarians, coupled with his extensive knowledge of the veterinary industry and his marketing expertise, is exactly what we need to succeed, stated Dr. Harman. I am happy to welcome him to be part of our leadership team.

About Vet-Stem, Inc. Vet-Stem, Inc. was formed in 2002 to bring regenerative medicine to the veterinary profession. This privately held biotechnology enterprise, based near San Diego (California), currently offers veterinarians access to stem-cell therapy (extracted from the patients own fat tissue), among other regenerative treatment modalities. With over 10,000 patients treated by veterinarians for joint, tendons and ligament issues, Vet-Stem has made regenerative medicine applications a therapeutic reality beyond the realm of research. Development programs focused on products and services that utilize the natural tissue healing properties inherent in all living creatures, have the potential to dramatically improve the quality of life for our animals Vet-Stems progress in bringing practical and affordable medical solutions to market might change animal lives by improving the quality of recovery in acute conditions, but also by unlocking ways to slow, stop and ultimately revert the course of chronic diseases.. Vet-Stem currently holds the exclusive licenses to over 55 patents including worldwide veterinary rights for use of adipose derived stem cells, with over 75 patents pending.

12860 Danielson Court, Suite B Poway, CA 92064 858-748-2004

Go here to see the original:
Vet-Stem, Inc. CEO announces hiring of President and Chief Commercial Officer (Dr. Alexis Nahama).

Nicholasville, Kentucky (PRWEB) January 16, 2015

MediVet Biologics a company known for their focus on companion animal health with world-class lab facilities was selected by the University of Kentuckys researchers to investigate the potential of a canine cancer treatment. The team of researchers in charge of developing the K-9 ACV veterinary cancer vaccine service have dedicated decades of research toward a better understanding of how the immune system responds to cancer cells with the goal of improving cancer treatment. Leading researcher John Yanelli, Ph.D has spent over 20 years conducting successful NIH-funded clinical trials in humans with lung cancer. Dr. Yannelli has published nearly 100 articles and book chapters on the immunotherapy of human cancer and continues research to improve immunotherapeutic approaches to treat cancer. With this strong knowledge base, this outstanding team now extends their efforts toward developing an effective and affordable personalized cancer vaccine service for veterinary medicine. MediVet Biologics has successfully implemented other cutting edge human medical grade technologies in the Veterinary space such as regenerative medicine in Veterinarian clinics across the world.

Nearly 6 million dogs are diagnosed with cancer every year and greater than fifty percent of dogs over the age of ten will eventually develop cancer, making cancer the leading cause of disease-related death in dogs. Many of the dogs diagnosed have no mode of viable treatment. Cancer screening for early detection in dogs lags far behind human medicine. Consequently, canine cancers are usually diagnosed in later stages of disease, making them more difficult to treat effectively and increasing the likelihood of recurrence. Therapeutic options for treatable tumors include surgery, chemotherapy and radiation therapy. The side effects associated with chemotherapy and radiation therapy can seriously affect quality of life, making it difficult for pet owners to justify current cancer treatments for their dogs. The average cancer treatment expense is over $5,000 and could be well over $35,000.

MediVet Biologics approach is to use the entire tumor cell as the basis for the vaccine. When combined with surgical resection of primary tumors, this activates the immune system, leading to better clinical outcomes for canine cancers. This form of immunotherapy, developed at the NCI by researchers, including Dr. John Yannelli, has been used at the University of Kentucky Markey Cancer Center to treat humans with advanced non-small cell lung cancer (J. Clin Oncol., 22:2808, 2004). Read more about K9-ACV in the February issue of VPN (Veterinary Practice News).

MediVet Biologics reputation and success with in-clinic stem cell therapy adaptation and development make them an excellent fit for an autologous canine tumor vaccine service. The service in which resected tumor tissue will be processed at The University of Kentucky and MediVets lab into a therapeutic vaccine to be administered to dogs with cancer is a personalized medicine approach. MediVet Labs is set-up for state of the art maneuverability with animal biologics as well as superior high-end quality controls, SOPs and protocols.

According to the CEO, Jeremy Delk, MediVet Biologics is excited to make this announcement and offer an additional service to our existing customers as well as future customers. Most of all we look forward to offering an affordable treatment alternative to the animals and owners that need it. This initiative is part of a broader research and development program with MediVet Biologics. Along with the further development and marketing of our veterinary and stem cell business in the United States, more announcements of novel products will come throughout the year.

Veterinarians and patients are being sought in vaccine efficacy studies. To inquire about enrolling a patient please contact MediVet Biologics.

About MediVet Biologics

MediVet Biologics headquartered just outside Lexington, KY and Sydney Australia is a subsidiary of Medical Australia (MLA: ASX). MediVet Biologics has global reach including established partners in 26 countries around the world as well as strong market positioning in North America. The company provides novel treatment options based in science to the Veterinary market and provides unique customer specific service plans to ensure implementation and growth of its progressive products and services.

Medivet Biologics' mission is to set standards of excellence providing biologic solutions to the veterinary market. Our companys success, which is characterized by responsiveness and clinical excellence, has been founded on our dedication and quality innovative technologies. Veterinarians and pet owners trust MediVet Biologics to provide the quality care they expect and deserve. By providing services as though each pet were a member of our family, MediVet Biologics strives to be the preferred provider of Veterinary Regenerative Medicine products, equipment and services.

Originally posted here:
Medivet Biologics launches newest service, K9-ACV a personalized medicine approach to canine cancer.

When pets have osteoarthritis, OA, veterinarians often recommend the same treatment plan that humans with OA are encouraged to follow: weight loss, exercise and nonsteroidal anti-inflammatory drugs, NSAIDs. But when these traditional methods of arthritis treatment fail in their dogs, some pet owners are turning to an option not yet available for people stem cell therapy.

In the cutting-edge treatment, a veterinarian surgically harvests about two tablespoons of fat cells from the dogs body and sends them to a lab. After the stem cells are isolated and returned within 24 hours, the vet injects them back into the dogs joints that have arthritis.

The hope is the injected cells will regenerate damaged joint tissue, but once they are injected it is not clear what they are doing in the joint, says Farshid Guilak, PhD, professor of orthopaedic surgery and biomedical engineering at Duke University Medical Center in Durham, N.C. A growing number of researchers, including Guilak, suspect they may help by reducing inflammation.

"There is a theory that is getting more and more support that these stem cells produce anti-inflammatory cytokines," says Guilak, who is studying stem cells in mice with arthritis.

Regardless of how the treatment might work, many pet owners are convinced it does. According to pet-owner surveys conducted by Vet-Stem, the only U.S. company that is currently processing fat stem cells for veterinarians, approximately 75 percent of dogs treated for arthritis have an improvement in quality of life after the treatment with possible relief lasting anywhere from six months to one year.

For veterinarians, however, the jury's still out on the therapy's usefulness. Some veterinarians dont believe the cost approximately $3,000 as well as the risks that accompany any surgical procedure, are worth the limited success rate.

We dont know if its even as good as NSAIDs [at relieving pain] and it certainly costs a lot more, says James Cook, professor of orthopaedic surgery at the University of Missouri College of Veterinary Medicine in Columbia. Until I see a lot better evidence, we dont use it and I dont recommend it.

But Darryl Millis, professor of orthopaedic surgery at the University of Tennessee College of Veterinary Medicine in Knoxville, sees the benefits of stem cell therapy, most notably for dogs that have not been helped by traditional means for relief.

Weve done it on severe cases that had already gone through all the basic treatments, says Millis. About three-quarters of the dogs responded well, showing less signs of pain and being much more active, he says. It is fairly costly but a lot of people are willing to spend that to have their pets lead a less painful life.

Might the same therapy be useful for people seeking a less painful life? Possibly but not for a while, says Guilak. "It seems promising, but it is very preliminary." Before using it in people, he says, doctors would need to better understand how it works and how to maximize results.

See the rest here:
Stem Cell Therapy | Stem Cell Therapy Pets ...

New York, NY (PRWEB) December 16, 2014

The Mount Sinai Health System today announced that Daniel S. Loeb, CEO and Founder of Third Point LLC, and his wife, Margaret Munzer Loeb, have made a $15 million gift to establish the Ronald M. Loeb Center for Alzheimers Disease in memory of Daniels father, Ronald M. Loeb. The Loeb Center will be a network of research programs, closely tied to clinical initiatives, across the Mount Sinai Health System.

The center will be led by Alison Goate, PhD, a highly regarded neuropsychiatric researcher and molecular geneticist. Dr. Goate will work in concert with three Mount Sinai faculty members who are world leaders in Alzheimers research and care: Mary Sano, PhD; Sam Gandy, MD, PhD; and Eric Schadt, PhD.

"I am honored to establish this new center in my fathers memory and to support groundbreaking research in Alzheimers disease, Mr. Loeb said. When my father was sick, I learned how painful this disease is for those afflicted and their families. I also recognized that there is little hope for patients today beyond slowing the progression of Alzheimers. We urgently need more resources to find a cure or effective prevention.

Mount Sinai has been at the forefront of Alzheimers research, starting with Dr. Ken Davis several decades ago, Mr. Loeb continued. It is my hope that this Center, with its multi-departmental approach and expertise in stem cell research and genomics, will bring together the best in the field to find the breakthrough we so urgently need.

"We are deeply grateful for the Loeb familys immense generosity and unique vision, which will help to enhance Mount Sinais reputation as one of the world's leading resources for all aspects of Alzheimers Disease research," said Mount Sinai CEO and President Kenneth L. Davis, MD. This gift will have an enormous positive effect on our ability to bring together our core competencies in Alzheimers disease research: genomics, bioinformatics, imaging and clinical trials.

I am so pleased to acknowledge Daniel Loeb for this historic gift, Dr. Davis continued. He is a leader with extraordinary talent and vision who brings passion to all that he does. Based in no small part on work done by Mount Sinai researchers, there has been a revolution in the way we think about Alzheimers disease, and that revolution has brought us to the threshold of major breakthroughs, which we will vigorously pursue at the Ronald M. Loeb Center, under the leadership of Dr. Alison Goate, who is truly one of the chief architects of the genomics revolution in Alzheimers disease.

The Ronald M. Loeb Center for Alzheimers Disease will bring together a network of researchers and clinicians from the entire Mount Sinai Health System. The Loeb Center will have substantial interactions with the Alzheimers Disease Research Center (ADRC), sponsored by the National Institute of Aging and directed by Dr. Sano, Associate Dean for Clinical Research and Professor of Psychiatry, Icahn School of Medicine at Mount Sinai. Physicians will primarily see patients in the Center for Cognitive Health (part of the May Center for Mount Sinai Doctors), led by Dr. Gandy, the Mount Sinai Professor in Alzheimers Research, Professor of Neurology and Psychiatry, and Associate Director, Mount Sinai Alzheimers Disease Research Center. The Loeb Centers research enterprise will be anchored on the 10th floor of the Icahn Medical Institute. The Center will closely collaborate with scientists at The Friedman Brain Institute, led by Eric Nestler, MD, PhD, the Nash Family Professor and Chair of Neuroscience; and the Icahn Institute for Genomics and Multiscale Biology; directed by Dr. Schadt, the Jean C. and James W. Crystal Professor of Genomics; among other research partners from across Mount Sinai.

Dr. Goate, who is the Mount Sinai Professor of Neuroscience and Genetics and Genomic Sciences and Director of the Loeb Center, is coming to Mount Sinai from the Washington University School of Medicine in St. Louis. She is renowned for identifying some of the key gene mutations linked to the heritable risk for Alzheimers disease, including her find that a rare mutation in the PLD3 gene doubles the risk of developing late onset Alzheimers disease (LOAD). She led a team of researchers who performed the largest ever genome-wide association study of protein markers found in cerebrospinal fluid, resulting in the discovery of three new genetic variants that may indicate the presence of Alzheimers disease.

As Director of the Ronald M. Loeb Center for Alzheimers Disease, Dr. Goate will have an immediate impact by catalyzing genomics and multiscale biology-based research projects focused on Alzheimers disease and strengthening Mount Sinais Alzheimers disease research infrastructure with new talent in areas such as induced pluripotent stem cells. Dr. Goate will also collaborate with the outstanding team of experts already in place at Mount Sinai. The team includes Dr. Sano, one of the nations leaders in clinical trials of Alzheimers disease, and Dr. Gandy, a foremost expert on the amyloid plaque protein linked to Alzheimers disease. Dr. Goate will also have access to the innovative new MRI and PET technology (Mount Sinai is one of the few sites in the U.S. with such advanced technology) and the Minerva supercomputer, the largest supercomputer ever constructed for the purpose of genomic investigation.

View post:
Gift to Mount Sinai Health System Establishes Ronald M. Loeb Center for Alzheimers Disease

ORLANDO, Fla. -

If you think your dog is suffering from arthritis, researchers at the University of Floridas Health Science Center want you.

[WEB EXTRA: See if your pet meets study criteria | More info on stem cell process ]

Well, actually your pet.

Your dog may be eligible for a blind study being conducted by the University of Floridas College of Veterinary Medicine.

UF veterinarians are looking for 30 dogs, ages 2 to 10 years old, to participate in the next phase of a stem cell therapy project.

The dogs must be healthy, 10 to 120 pounds, and should have been diagnosed with elbow arthritis or dysplasia by their local vet.

Doctors are injecting stem cells directly into the elbows (front leg joints) of the animals to determine if the treatment will decrease the inflammation and pain associated with elbow dysplasia.

Dr. Stanley Kim, a specialist in small animal surgery, says some pets are given a placebo and not even the owner will know if saline or stem cells have been injected into the pets joints until the 6 month study is completed.

The dogs are evaluated at one month, three months and then again at six months but no dog will be left without the stem cell therapy.

Read more here:
UF researchers recruiting local pets for arthritis study

FORT COLLINS, Colo. (CBS4) Researchers at Colorado State University are using stem cell therapy to treat kidney disease in cats. Theyre hoping to learn if stem cells can stop the progression of the disease.

Its the first feline stem cell program in the country which offers hope for the estimated 75 million pet cats in the U.S.

As cats age, a third or more develop chronic kidney disease. The studies underway at CSU may help both the cats and eventually their humans.

Squeakers (credit: CBS)

Squeakers is a domestic short hair, 15 years old, part Siamese and ill.

Shes actually just recently diagnosed with chronic kidney disease, said veterinarian Dr. Jessica Quimby.

There is no cure for feline kidney disease except a transplant, so Squeakers owner has entrusted her to the veterinarians at CSU.

Her kidneys are a little bit smallish and a little irregular, said Quimby.

For five years, Quimby and her colleagues have been running clinical trials on cats in the early stages of kidney disease. They inject them with stem cells harvested from the fat of healthy cats.

Weve seen variable results. Some kittens do get a little bit improvement in their kidney function, said Quimby. Right after we give the stem cells sometimes its just the same.

Read more here:
CSU Researchers Using Stem Cell Therapy To Treat Kidney Disease In Cats

Stem Cell Treatment For Arthritis Get Pet Bounce here http://tinyurl.com/ocrto6x Pet Bounce is an all-natural, plant-based homeopathic blend designed to help alleviate the symptoms your pet may be experiencing safely By: valeria nsijko Continue reading

Source Link(s) Are Here

Stem Cell Treatment For Arthritis - Video

Stem Cell Therapy: Dr. Roberta Shapiro A NY Physician's Path to Panama Special Guest Speaker, Roberta F. Shapiro DO, FAAPM R speaks about: A New York Doctor's Path to Panama at the Stem Cell Institute's Stem Cell Therapy Publi Continue reading

Source Link(s) Are Here

Stem Cell Therapy: Dr. Roberta Shapiro - A NY Physician's Path to Panama - Video

NEW YORK, Nov. 21, 2014 /PRNewswire/ Because Alzheimer's disease kills brain cells, some scientists believe that stem cells, which have the ability to regenerate brain and other similar cells, may one .. Continue reading

Source Link(s) Are Here

Kalorama: Stem Cell Therapies Hold Hope for Alzheimer's Treatments

AVON LAKE, OH (WOIO) When Shannon Gouldings bloodhound Butler tore a ligament in his knee his entire personality changed. He was sedentary, and he wasnt as active as before, said Goulding. Continue reading

Read more from the original source:
Stem Cell Treatment for Multiple Sclerosis

Q: You recently wrote about stem cell research, and I understand that stem cell therapy is being used to treat inflammatory bowel disease in cats. Do you have more details?

A: The Winn Feline Foundation has funded the research of Dr. Craig Webb and Dr. Tracy Webb of Colorado State University College of Veterinary Medicine to study the use of stem cells to treat inflammatory bowel disease in cats. Early results are promising.

Stem cell research in cats doesn't stop there. Dr. Glenn Olah, president of the Winn Feline Foundation, notes that Winn also funded stem cell studies to treat feline asthma and kidney disease. Results are hopeful, but it's simply too early to offer definitive answers.

"In some ways, stem cell studies in pets are ahead of (those in) people."

Q: About a month ago, I adopted a beautiful Burmese after she romanced me at the shelter. Once we got home, she wanted nothing to do with me. It's not that she isn't friendly. She loves my son and even sleeps with him. When I get up early to feed her, she stays away until I've left the room. My son suggested that the cat harbors resentment toward me because I took her from her cat friends. What can do to improve the situation?

A: "The good news is that it's very unlikely the cat harbors any resentment," said Winn Feline board member and feline veterinarian Dr. Drew Weigner, of Atlanta. "The bad news for you -- but good news for the cat and your son -- is that they developed a fast friendship.

Here are tips that might help the cat warm up to you:

Sit on the floor in an empty room with her. Close the door, but provide an empty box or two for the cat to hop into. Then, simply watch TV, or read a children's story out loud. Cats sometimes like that soft sing-song voice we tend to use when reading children's stories.

Wait until the cat comes to you. It may take several days, but eventually curiosity will out.

Next, take over feeding the cat, even if she waits for you to leave the room to eat.

Excerpt from:
My Pet World: Stem cell treatments show promise for some feline health issues

World's First Affordable In-House Stem Cell Procedure Kit

What is stem cell therapy? Stem cells are the bodys repair cells. They have the ability to divide and differentiate into many different types of cells based on where they are needed throughout the body. Stem cells can divide and turn into tissues such as skin, fat, muscle, bone, cartilage, and nerve to name a few. They even possess the ability to replicate into organs such as the heart, liver, intestines, pancreas, etc.

What are the different types of stem cells? There are two basic types of stem cells; embryonic and somatic (adult). Embryonic stem cells are found in the placenta and embryo. These cells are called totipotent, which means they have the ability to reproduce into any mature cell type. While embryonic stem cells offer the greatest potential in healing, there are obviously moral and ethical concerns in harvesting these cells.

The second type of stem cell is the adult stem cell. These stem cells are called multipotent, which means they can differentiate into closely related cell lines, but they are not capable of creating a complete organ. Adult stem cells are found in the bone marrow, adipose tissue (fat), skin, liver, blood vessels, and neurons. Contrary to embryonic stem cells, there are no moral or ethical concerns in harvesting these cells, activating them, and reintroducing them back to the patient in areas where healing and regeneration is needed.

So why do we take the cells from adipose (fat) tissue? Adult stem cells are highly concentrated in the fat tissue. There are 50 to 1,000 times more stem cells in the fat than the bone marrow. At this concentration, it is no longer necessary to culture the stem cells to acquire the necessary cell numbers to make a healing impact. The procedure to extract fat from the patient is much quicker and less invasive than a spay. The stem cells are contained within a pool of cells in the fat termed the Stromal Vascular Fraction (SVF). The SVF may impart anti-inflammatory effects, add bioactive peptides, and contribute to reformation and architectural organization. These are benefits lost once stem cells are cultured.

So what can we do with the stem cells? Adult stem cells are capable of dividing into many different cell types. With this capability, we can use them as a treatment for joint injuries, ligament and tendon damage, and fractured bones. Research and clinical trials currently support the use of stem cells in these conditions. Ongoing research is targeting other areas of the body for treatment and the preliminary results are very encouraging.

So what makes MediVet Americas technology better? With our patented LED technology and by incorporating Platelet-Rich Plasma (PRP) the same treatment used by many sports professionals, Veterinary Stem Cell, Stem Cell Therapy for Pets, Adipose Stem Cell Therapy, Platelet Rich Plasma Horses, Adipose Stem Cell Treatment, Platelet Rich Plasma Dogs is able to acquire the most living stem cells of any company currently offering this technology. If your beloved pet is going to have to endure the surgical procedure, we want to make sure they are going to get the most out of it! Veterinary Stem Cell, Stem Cell Therapy for Pets, Adipose Stem Cell Therapy, Platelet Rich Plasma Horses, Adipose Stem Cell Treatment, Platelet Rich Plasma Dogs also offers Cryobanking, where you can store extra cells from the procedure for future use.

So how will the procedure work? The day of the procedure, the veterinarian will anesthetize your pet. They will surgically remove a couple tablespoons of fat. This is a quick and simple procedure that is generally easier than performing a spay. They will then process the fat to remove the stem cells. Processing generally takes a couple of hours. After the stem cells have been collected, your pet will generally be sedated and the stem cells will be administered into the affected joints and/or into the bloodstream. It is important that you do not feed your pet the night before the procedure.

When will I see results? We expect you to see results! While we know every animal is different and there are no guarantees, we have seen positive clinical improvement in 95% of the arthritic cases performed nationwide. Some owners have even reported seeing a difference in as little as a week! While quick results are possible, we expect you to begin seeing improvement within the first 90 days following treatment. Really bad arthritis may require multiple injections, so banking your extra cells is always a good idea!

Is this procedure safe? As with any procedure that involves anesthesia, there is always a risk. However, the stem cells are coming from your pet and are being re-administered back to your pet. There is no risk of an allergic reaction. In rare casesthere might be a mild immune reaction in the injected joint that should subside within a day or two.

Continued here:
Medivet - Veterinary Stem Cell, Stem Cell Therapy for Pets ...